Literature DB >> 24773058

Type III interferons are expressed by Coxsackievirus-infected human primary hepatocytes and regulate hepatocyte permissiveness to infection.

K Lind1, E Svedin, R Utorova, V M Stone, M Flodström-Tullberg.   

Abstract

Hepatitis is a common and potentially fatal manifestation of severe Coxsackievirus infections, particularly in newborn children. Little is known of the immune-mediated mechanisms regulating permissiveness to liver infection. It is well established that type I interferons (IFNs) play an important role in the host innate immune response to Coxsackievirus infections. Recent studies have highlighted a role for another IFN family, the type III IFNs (also called IFN-λ), in anti-viral defence. Whether type III IFNs are produced by hepatocytes during a Coxsackievirus infection remains unknown. Moreover, whether or not type III IFNs protects hepatocytes from a Coxsackievirus infection has not been addressed. In this study, we show that primary human hepatocytes respond to a Coxsackievirus B3 (CVB3) infection by up-regulating the expression of type III IFNs. We also demonstrate that type III IFNs induce an anti-viral state in hepatocytes characterized by the up-regulated expression of IFN-stimulated genes, including IFN-stimulated gene (ISG15), 2'-5'-oligoadenylate synthetase 2 (OAS2), protein kinase regulated by dsRNA (PKR) and myxovirus resistance protein 1 (Mx1). Furthermore, our study reveals that type III IFNs attenuate CVB3 replication both in hepatocyte cell lines and primary human hepatocytes. Our studies suggest that human hepatocytes express type III IFNs in response to a Coxsackievirus infection and highlight a novel role for type III IFNs in regulating hepatocyte permissiveness to this clinically relevant type of virus.
© 2014 British Society for Immunology.

Entities:  

Keywords:  Coxsackievirus; anti-viral defence; enterovirus; hepatocytes; interferons

Mesh:

Substances:

Year:  2014        PMID: 24773058      PMCID: PMC4137853          DOI: 10.1111/cei.12368

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  35 in total

1.  IL-28, IL-29 and their class II cytokine receptor IL-28R.

Authors:  Paul Sheppard; Wayne Kindsvogel; Wenfeng Xu; Katherine Henderson; Stacy Schlutsmeyer; Theodore E Whitmore; Rolf Kuestner; Ursula Garrigues; Carl Birks; Jenny Roraback; Craig Ostrander; Dennis Dong; Jinu Shin; Scott Presnell; Brian Fox; Betty Haldeman; Emily Cooper; David Taft; Teresa Gilbert; Francis J Grant; Monica Tackett; William Krivan; Gary McKnight; Chris Clegg; Don Foster; Kevin M Klucher
Journal:  Nat Immunol       Date:  2002-12-02       Impact factor: 25.606

2.  Use of human hepatocytes to study P450 gene induction.

Authors:  S C Strom; L A Pisarov; K Dorko; M T Thompson; J D Schuetz; E G Schuetz
Journal:  Methods Enzymol       Date:  1996       Impact factor: 1.600

3.  IFN-lambdas mediate antiviral protection through a distinct class II cytokine receptor complex.

Authors:  Sergei V Kotenko; Grant Gallagher; Vitaliy V Baurin; Anita Lewis-Antes; Meiling Shen; Nital K Shah; Jerome A Langer; Faruk Sheikh; Harold Dickensheets; Raymond P Donnelly
Journal:  Nat Immunol       Date:  2002-12-16       Impact factor: 25.606

4.  Cardioselective infection with coxsackievirus B3 requires intact type I interferon signaling: implications for mortality and early viral replication.

Authors:  R Wessely; K Klingel; K U Knowlton; R Kandolf
Journal:  Circulation       Date:  2001-02-06       Impact factor: 29.690

5.  Nitric oxide inhibits viral replication in murine myocarditis.

Authors:  C J Lowenstein; S L Hill; A Lafond-Walker; J Wu; G Allen; M Landavere; N R Rose; A Herskowitz
Journal:  J Clin Invest       Date:  1996-04-15       Impact factor: 14.808

6.  RNase L and double-stranded RNA-dependent protein kinase exert complementary roles in islet cell defense during coxsackievirus infection.

Authors:  Malin Flodström-Tullberg; Monica Hultcrantz; Alexandr Stotland; Amy Maday; Devin Tsai; Cody Fine; Bryan Williams; Robert Silverman; Nora Sarvetnick
Journal:  J Immunol       Date:  2005-02-01       Impact factor: 5.422

7.  Hepatic damage caused by coxsackievirus B3 is dependent on age-related tissue tropisms associated with the coxsackievirus-adenovirus receptor.

Authors:  Jung-Yen Liu; Shih-Min Wang; I-Chun Chen; Chun-Keung Yu; Ching-Chuan Liu
Journal:  Pathog Dis       Date:  2013-06-07       Impact factor: 3.166

8.  Lambda interferon inhibits hepatitis B and C virus replication.

Authors:  Michael D Robek; Bryan S Boyd; Francis V Chisari
Journal:  J Virol       Date:  2005-03       Impact factor: 5.103

9.  Neonatal enterovirus infections: emphasis on risk factors of severe and fatal infections.

Authors:  Tzou-Yien Lin; Hsiu-Tsun Kao; Shang-Hong Hsieh; Yhu-Chering Huang; Cheng-Hsun Chiu; Yi-Hong Chou; Peng-Hong Yang; Rey-In Lin; Kuo-Chien Tsao; Kuang-Hung Hsu; Luan-Yin Chang
Journal:  Pediatr Infect Dis J       Date:  2003-10       Impact factor: 2.129

10.  Protective role for interferon-beta in coxsackievirus B3 infection.

Authors:  Raj Deonarain; Dante Cerullo; Koichi Fuse; Peter P Liu; Eleanor N Fish
Journal:  Circulation       Date:  2004-07-12       Impact factor: 29.690

View more
  8 in total

Review 1.  Interferon-λ orchestrates innate and adaptive mucosal immune responses.

Authors:  Liang Ye; Daniel Schnepf; Peter Staeheli
Journal:  Nat Rev Immunol       Date:  2019-06-14       Impact factor: 53.106

Review 2.  Innate Immunity and Immune Evasion by Enterovirus 71.

Authors:  Prabuddha S Pathinayake; Alan C-Y Hsu; Peter A B Wark
Journal:  Viruses       Date:  2015-12-14       Impact factor: 5.048

Review 3.  Molecular Pathogenicity of Enteroviruses Causing Neurological Disease.

Authors:  Anna Majer; Alan McGreevy; Timothy F Booth
Journal:  Front Microbiol       Date:  2020-04-09       Impact factor: 5.640

4.  Inhibition of Type III Interferon Expression in Intestinal Epithelial Cells-A Strategy Used by Coxsackie B Virus to Evade the Host's Innate Immune Response at the Primary Site of Infection?

Authors:  Virginia M Stone; Emma E Ringqvist; Pär G Larsson; Erna Domsgen; Ulrika Holmlund; Eva Sverremark-Ekström; Malin Flodström-Tullberg
Journal:  Microorganisms       Date:  2021-01-05

Review 5.  The Key Roles of Interferon Lambda in Human Molecular Defense against Respiratory Viral Infections.

Authors:  Alexey A Lozhkov; Sergey A Klotchenko; Edward S Ramsay; Herman D Moshkoff; Dmitry A Moshkoff; Andrey V Vasin; Maria S Salvato
Journal:  Pathogens       Date:  2020-11-26

6.  A Link Between a Common Mutation in CFTR and Impaired Innate and Adaptive Viral Defense.

Authors:  Emma Svedin; Renata Utorova; Michael H Hühn; Pär G Larsson; Virginia M Stone; Manasa Garimella; Katharina Lind; Thomas Hägglöf; Terezia Pincikova; Olli H Laitinen; Gerald M McInerney; Bob Scholte; Lena Hjelte; Mikael C I Karlsson; Malin Flodström-Tullberg
Journal:  J Infect Dis       Date:  2017-12-05       Impact factor: 5.226

7.  Interferon-beta expression and type I interferon receptor signaling of hepatocytes prevent hepatic necrosis and virus dissemination in Coxsackievirus B3-infected mice.

Authors:  Wolfgang Koestner; Julia Spanier; Tanja Klause; Pia-K Tegtmeyer; Jennifer Becker; Vanessa Herder; Katharina Borst; Daniel Todt; Stefan Lienenklaus; Ingo Gerhauser; Claudia N Detje; Robert Geffers; Martijn A Langereis; Florian W R Vondran; Qinggong Yuan; Frank J M van Kuppeveld; Michael Ott; Peter Staeheli; Eike Steinmann; Wolfgang Baumgärtner; Frank Wacker; Ulrich Kalinke
Journal:  PLoS Pathog       Date:  2018-08-03       Impact factor: 6.823

Review 8.  Enteroviral proteases: structure, host interactions and pathogenicity.

Authors:  Olli H Laitinen; Emma Svedin; Sebastian Kapell; Anssi Nurminen; Vesa P Hytönen; Malin Flodström-Tullberg
Journal:  Rev Med Virol       Date:  2016-05-04       Impact factor: 6.989

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.